These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22708263)

  • 1. [JSNP Excellent Presentation Award for AsCNP 2011: improvement of cognitive impairments on withdrawal after repeated methamphetamine by administration of a cannabinoid CB1 receptor antagonist and a COX inhibitor].
    Nawata Y; Yamaguchi T; Yamamoto T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Apr; 32(2):93-4. PubMed ID: 22708263
    [No Abstract]   [Full Text] [Related]  

  • 2. A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy).
    Nawata Y; Hiranita T; Yamamoto T
    Neuropsychopharmacology; 2010 Jan; 35(2):515-20. PubMed ID: 19829291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice.
    Landa L; Sulcova A; Slais K
    Neuro Endocrinol Lett; 2006; 27(1-2):63-9. PubMed ID: 16648795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
    Cook SA; Lowe JA; Martin BR
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.
    Croci T; Landi M; Galzin AM; Marini P
    Br J Pharmacol; 2003 Sep; 140(1):115-22. PubMed ID: 12967941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.
    López-Moreno JA; González-Cuevas G; Navarro M
    Neurobiol Dis; 2007 Feb; 25(2):274-83. PubMed ID: 17067804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cannabinoid receptor ligands on behavioural sensitization to antiaggressive methamphetamine effects in the model of mouse agonistic behaviour.
    Landa L; Slais K; Sulcova A
    Neuro Endocrinol Lett; 2006 Dec; 27(6):703-10. PubMed ID: 17187025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding.
    Boctor SY; Martinez JL; Koek W; France CP
    Eur J Pharmacol; 2007 Sep; 571(1):39-43. PubMed ID: 17628534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach.
    Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2005 Dec; 1066(1-2):201-5. PubMed ID: 16336946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered dopamine D1 and D2 receptor mRNA expression in mesencephalon from mice exposed to repeated treatments with methamphetamine and cannabinoid CB1 agonist methanandamide.
    Landa L; Jurajda M; Sulcova A
    Neuro Endocrinol Lett; 2012; 33(4):446-52. PubMed ID: 22936253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
    Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade.
    Anggadiredja K; Nakamichi M; Hiranita T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Neuropsychopharmacology; 2004 Aug; 29(8):1470-8. PubMed ID: 15085091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precipitated withdrawal counters the adverse effects of subchronic cannabinoid administration on male rat sexual behavior.
    Riebe CJ; Lee TT; Hill MN; Gorzalka BB
    Neurosci Lett; 2010 Mar; 472(3):171-4. PubMed ID: 20138966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice.
    Comelli F; Bettoni I; Colombo A; Fumagalli P; Giagnoni G; Costa B
    Eur J Pharmacol; 2010 Jul; 637(1-3):62-9. PubMed ID: 20399204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
    Griebel G; Stemmelin J; Scatton B
    Biol Psychiatry; 2005 Feb; 57(3):261-7. PubMed ID: 15691527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CB(1) receptor antagonist, AM281, improves recognition loss induced by naloxone in morphine withdrawal mice.
    Vaseghi G; Rabbani M; Hajhashemi V
    Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):161-5. PubMed ID: 22429707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.